IGMS IGM Biosciences
- 8.330
- -0.380-4.36%
- 8.480
- +0.150+1.80%
IGM Biosciences News
IGM Biosciences to Present at the Jefferies Healthcare Conference
MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred
In-Depth Examination Of 6 Analyst Recommendations For IGM Biosciences
IGM Biosciences (NASDAQ:IGMS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below offers a condensed view of the
H.C. Wainwright Maintains IGM Biosciences(IGMS.US) With Hold Rating, Maintains Target Price $12
H.C. Wainwright analyst Robert Burns maintains $IGM Biosciences(IGMS.US)$ with a hold rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 23.4%
IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Maintaining Hold on IGM Biosciences: Assessing Acquisition Impact and Awaiting Clinical Data
HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates IGM Biosciences (NASDAQ:IGMS) with a Neutral and maintains $12 price target.
Jefferies Maintains IGM Biosciences(IGMS.US) With Buy Rating, Maintains Target Price $48
Jefferies analyst Roger Song maintains $IGM Biosciences(IGMS.US)$ with a buy rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success rate of 31.7% and a tot
IGM Biosciences IGMS +36% Acquisition Rumors; Biodexa BDRX -45% Warrants Exercise
IGM Biosciences up 40% Following Biogen HI-Bio Buy
CureVac, Oragenics, IGM Biosciences Among Healthcare Movers
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share.
MEME stocks are back strongly! GME surged nearly 180% in two days. Who will be next?
The agency believes that more retail traders will join this trend in the next few days, but the possibility of reaching the level of 2021 is still relatively low.
IGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns With EPS Projections Amidst Clinical ...
Wedbush: Reiterates IGM Biosciences (IGMS.US) rating and adjusted from superior to superior market rating, with a target price of $20.00.
Wedbush: Reiterates IGM Biosciences (IGMS.US) rating and adjusted from superior to superior market rating, with a target price of $20.00.
Wedbush Reiterates Outperform on IGM Biosciences, Maintains $20 Price Target
Wedbush analyst Robert Driscoll reiterates IGM Biosciences (NASDAQ:IGMS) with a Outperform and maintains $20 price target.
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN)
RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk
IGM Biosciences (IGMS) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $12 to $48.
IGM Biosciences Q1 EPS $(0.83), Inline, Sales $497.00K Miss $760.00K Estimate
IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(0.83) per share which met the analyst consensus estimate. This is a 37.59 percent increase over losses of $(1.33) per share from the same p
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000
04:42 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000
Analysis
Price Target
No Data
